Sarcopenia
Welcome,         Profile    Billing    Logout  
 46 Companies   12 Products   12 Products   17 Mechanisms of Action   756 Trials   22406 News 


«12...133134135136137138139140141142143...401402»
  • ||||||||||  New trial, HEOR:  QOL and Sarcopenia in Patients With Ascites (clinicaltrials.gov) -  Feb 14, 2023   
    P=N/A,  N=70, Not yet recruiting, 
  • ||||||||||  Enrollment open:  Low Versus High-intensity Exercises in Sarcopenia (clinicaltrials.gov) -  Feb 14, 2023   
    P=N/A,  N=80, Recruiting, 
    The characteristic aging phenotype observed in ACE2 KO mice was not reproduced in Mas KO mice, angiotensin 1-7 receptor-deficient mice or in Tsukuba hypertensive mice, a model of chronic angiotensin II overproduction, suggesting that the antiaging functions of ACE2 are independent of the renin-angiotensin system (RAS). Not yet recruiting --> Recruiting
  • ||||||||||  Enrollment closed, Trial completion date, Trial initiation date, Trial primary completion date, Surgery:  Mortality Predictions With Scorring Indices in Gastrointestinal Tumours (clinicaltrials.gov) -  Feb 14, 2023   
    P=N/A,  N=110, Active, not recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> May 2023 | Initiation date: Oct 2022 --> Feb 2023 | Trial primary completion date: Dec 2022 --> Apr 2023
  • ||||||||||  Soft matter actuators for muscle-replacement applications (Grand 1 (The Westin Indianapolis)) -  Feb 14, 2023 - Abstract #ACSSp2023ACS_SP_11000;    
    Simple actuation tests show the validity of our approach for in-body actuation. However, several challenges (including biocompatibility) will have to be addressed in the future.
  • ||||||||||  THE UNDERDIAGNOSED DISEASE IN HAEMOPHILIA: SARCOPENIA AND ULTRASOUND () -  Feb 13, 2023 - Abstract #EAHAD2023EAHAD_252;    
    Changes in joint range of motions, strength and reaction time have been tied to declines in mobility.These are critical factors in balance impairments and fall risk associated. Sarcopenia leads to muscle weakness, impaired gait and balance.We want to highlight the importance of MskUs as a tool for detecting and monitoring muscle volume loss in order to help maintain muscle functionality and joint preservation.
  • ||||||||||  Journal:  Symptoms of Sarcopenia and Physical Fitness through the Senior Fitness Test. (Pubmed Central) -  Feb 12, 2023   
    The first is dedicated to skeletal muscle pathophysiology, the second to disease mechanisms, and the third to therapeutic development. Physical fitness assessed through the senior fitness test, particularly the 30-s-arm curl test and the 6-min walk test, can discriminate for suspected symptoms of sarcopenia.
  • ||||||||||  Review, Journal:  Prevalence and Mechanisms of Skeletal Muscle Atrophy in Metabolic Conditions. (Pubmed Central) -  Feb 12, 2023   
    Depending on the pathological condition, either oxidative or glycolytic muscle type may be affected to a greater extent. This review article discusses the prevalence of skeletal muscle atrophy and several mechanisms, with an emphasis on high-fat, high-sugar diet patterns, obesity, and diabetes, but including other conditions such as sarcopenia, Alzheimer's disease, cancer cachexia, and heart failure.
  • ||||||||||  Journal:  Serum Myostatin among Excessive Drinkers. (Pubmed Central) -  Feb 12, 2023   
    We also observed higher myostatin values among patients with body mass index > 30 kg/m. Serum myostatin was lower among excessive drinkers, and it was related to increased fat deposition among these patients but not to lean mass, handgrip, or bone mineral density.
  • ||||||||||  Journal:  Morbidity Associated with Chronic Hyponatremia. (Pubmed Central) -  Feb 12, 2023   
    Patients with chronic hyponatremia are more likely to develop cancer. We will not review the clinical consequences of respiratory arrest and osmotic demyelination syndrome (ODS) of the too-late or excessive treatment of hyponatremia.
  • ||||||||||  Review, Journal:  Old and New Precipitants in Hepatic Encephalopathy: A New Look at a Field in Continuous Evolution. (Pubmed Central) -  Feb 12, 2023   
    Among the historically well-known precipitants, such as infections, gastrointestinal bleeding, dehydration, electrolyte disorders and constipation, recent studies have highlighted the role of malnutrition and portosystemic shunts as new precipitating factors of HE. The identification, management and correction of these factors are fundamental for effective HE treatment, in addition to pharmacological therapy with non-absorbable disaccharides and/or antibiotics.
  • ||||||||||  Journal:  Identification and Characterization of Genomic Predictors of Sarcopenia and Sarcopenic Obesity Using UK Biobank Data. (Pubmed Central) -  Feb 12, 2023   
    Furthermore, the literature data suggest that single-bout resistance exercise may induce significant changes in the expression of 26 of the 73 implicated genes in m. vastus lateralis, which may partly explain beneficial effects of strength training in the prevention and treatment of sarcopenia. In conclusion, we have identified and characterized 78 SNPs associated with sarcopenia and 55 SNPs with sarcopenic obesity in European-ancestry individuals from the UK Biobank.
  • ||||||||||  Journal:  SARCOPENIA IS A FREQUENT DISEASE IN SARS-COV-2 INFECTION. (Pubmed Central) -  Feb 10, 2023   
    More than 40% of our patients suffered from sarcopenia, which was associated with ageing, depression, low body mass index, reduction in functional autonomy and being a woman. Such data provide evidence for the need to assist hospitalized COVID-19 patients by means of a multidisciplinary specialist team.
  • ||||||||||  Adlumiz (anamorelin) / Helsinn, Ono Pharma
    Review, Journal, Metastases:  The landscape of cancer cachexia in advanced non-small cell lung cancer: a narrative review. (Pubmed Central) -  Feb 10, 2023   
    Currently, a ghrelin-like agonist, anamorelin, is approved for the treatment of cancer cachexia and is used in clinical practice in Japan...Cancer cachexia remains a poorly understood phenomenon, and awareness must be raised through educational activities for health care providers and patient family members. In addition, new therapeutics targeting cancer cachexia, such as GDF-15 antibodies, are in development, and further progress is expected.